Despite treatment with statins, many patients with elevated cholesterol levels will still develop cardiovascular disease. It is apparent that not only cholesterol but also the immune system plays an important role in the development of atherosclerosis. Researchers now provide a novel potential explanation for this residual cardiovascular risk, related to persistent activation of the immune system in patients with hypercholesterolemia who are treated with statins.